{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T15:26:22Z","timestamp":1771514782375,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T00:00:00Z","timestamp":1601337600000},"content-version":"vor","delay-in-days":637,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["HI17C2085"],"award-info":[{"award-number":["HI17C2085"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2019]]},"DOI":"10.1136\/esmoopen-2019-000575","type":"journal-article","created":{"date-parts":[[2019,11,29]],"date-time":"2019-11-29T04:45:12Z","timestamp":1575002712000},"page":"e000575","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Clinical insights on outcomes of corticosteroid administration in immune checkpoint inhibitor-induced pneumonitis by retrospective case series analysis"],"prefix":"10.1016","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7125-9795","authenticated-orcid":false,"given":"Changhee","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8196-4247","authenticated-orcid":false,"given":"Bhumsuk","family":"Keam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soon Ho","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chan-Young","family":"Ock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sun Mi","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miso","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Sik","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae Min","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Do-Youn","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong-Wan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Whan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dae Seog","family":"Heo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yung-Jue","family":"Bang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1136\/esmoopen-2019-000575_bb0010","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2019-000575_bb0015","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2019-000575_bb0020","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2019-000575_bb0025","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1056\/NEJMoa1613493","article-title":"First-Line nivolumab in stage IV or recurrent non\u2013small-cell lung cancer","volume":"376","author":"Carbone","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2019-000575_bb0030","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-Related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2019-000575_bb0035","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","article-title":"Pneumonitis in patients treated with Anti\u2013Programmed Death-1\/Programmed death ligand 1 therapy","volume":"35","author":"Naidoo","year":"2017","journal-title":"JCO"},{"key":"10.1136\/esmoopen-2019-000575_bb0040","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.lungcan.2016.12.016","article-title":"Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer","volume":"104","author":"Kato","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1136\/esmoopen-2019-000575_bb0045","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00050-2017","article-title":"Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients","volume":"50","author":"Delaunay","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1136\/esmoopen-2019-000575_bb0050","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1001\/jamaoncol.2016.2453","article-title":"Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer a systematic review and meta-analysis","volume":"2","author":"Nishino","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1136\/esmoopen-2019-000575_bb0055","author":"National Cancer Institute (NCI)"},{"key":"10.1136\/esmoopen-2019-000575_bb0060","series-title":"NCCN guidelines version 1.2018","author":"Thompson","year":"2018"},{"key":"10.1136\/esmoopen-2019-000575_bb0065","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jtho.2018.11.016","article-title":"Impact of checkpoint inhibitor pneumonitis on survival in NSCLC patients receiving immune checkpoint immunotherapy","volume":"14","author":"Suresh","year":"2019","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1136\/esmoopen-2019-000575_bb0070","doi-asserted-by":"crossref","first-page":"e004587","DOI":"10.1136\/bmjopen-2013-004587","article-title":"Corticosteroids and risk of gastrointestinal bleeding: a systematic review and meta-analysis","volume":"4","author":"Narum","year":"2014","journal-title":"BMJ Open"},{"key":"10.1136\/esmoopen-2019-000575_bb0075","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.rdc.2015.08.004","article-title":"Infection risk and safety of corticosteroid use","volume":"42","author":"Youssef","year":"2016","journal-title":"Rheumatic Disease Clinics of North America"},{"key":"10.1136\/esmoopen-2019-000575_bb0080","article-title":"Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study","volume":"357","author":"Waljee","year":"2017","journal-title":"BMJ"},{"key":"10.1136\/esmoopen-2019-000575_bb0085","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.4239\/wjd.v6.i8.1073","article-title":"Steroid hyperglycemia: prevalence, early detection and therapeutic recommendations: a narrative review","volume":"6","author":"Tamez-P\u00e9rez","year":"2015","journal-title":"World J Diabetes"},{"key":"10.1136\/esmoopen-2019-000575_bb0090","doi-asserted-by":"crossref","first-page":"521","DOI":"10.18632\/aging.100797","article-title":"Corticosteroids and immune checkpoint blockade","volume":"7","author":"Min","year":"2015","journal-title":"Aging"},{"key":"10.1136\/esmoopen-2019-000575_bb0095","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.critrevonc.2017.10.009","article-title":"Concomitant use of corticosteroids and immune checkpoint inhibitors in patients with hematologic or solid neoplasms: a systematic review","volume":"120","author":"Garant","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1136\/esmoopen-2019-000575_bb0100","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1200\/JCO.19.00189","article-title":"Immune checkpoint inhibitor outcomes for patients with Non\u2013Small-Cell lung cancer receiving baseline corticosteroids for palliative versus Nonpalliative indications","volume":"37","author":"Ricciuti","year":"2019","journal-title":"JCO"},{"key":"10.1136\/esmoopen-2019-000575_bb0105","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1001\/jamaoncol.2019.1022","article-title":"Evaluation of Readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer","volume":"5","author":"Simonaggio","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1136\/esmoopen-2019-000575_bb0110","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1136\/esmoopen-2019-000575_bb0115","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","article-title":"An official American thoracic Society\/European respiratory Society statement: update of the International multidisciplinary classification of the idiopathic interstitial pneumonias","volume":"188","author":"Travis","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1136\/esmoopen-2019-000575_bb0120","first-page":"518","article-title":"American thoracic Society American thoracic Society \/ European respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias","volume":"166","author":"Society ATSR","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1136\/esmoopen-2019-000575_bb0125","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1164\/rccm.201202-0320ST","article-title":"An official American thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease","volume":"185","author":"Meyer","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1136\/esmoopen-2019-000575_bb0130","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.lungcan.2016.07.010","article-title":"Nivolumab-induced organizing pneumonitis in a patient with lung sarcomatoid carcinoma","volume":"99","author":"Gounant","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1136\/esmoopen-2019-000575_bb0135","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1002\/cam4.1579","article-title":"Risk factors for pneumonitis in patients treated with anti-programmed death-1 therapy: a case-control study","volume":"7","author":"Cui","year":"2018","journal-title":"Cancer Med"},{"key":"10.1136\/esmoopen-2019-000575_bb0140","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/CMR.0000000000000355","article-title":"Late-Onset nivolumab-mediated pneumonitis in a patient with melanoma and multiple immune-related adverse events","volume":"27","author":"Diamantopoulos","year":"2017","journal-title":"Melanoma Res"},{"key":"10.1136\/esmoopen-2019-000575_bb0145","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.9012","article-title":"Safety of retreatment with immunotherapy after immune-related toxicity in patients with lung cancers treated with anti-PD(L)-1 therapy","volume":"35","author":"Santini","year":"2017","journal-title":"JCO"},{"key":"10.1136\/esmoopen-2019-000575_bb0150","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2020","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702920300909?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702920300909?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/esmoopen-2019-000575","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:22:40Z","timestamp":1761855760000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702920300909"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019]]}},"alternative-id":["S2059702920300909"],"URL":"https:\/\/doi.org\/10.1136\/esmoopen-2019-000575","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2019]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical insights on outcomes of corticosteroid administration in immune checkpoint inhibitor-induced pneumonitis by retrospective case series analysis","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/esmoopen-2019-000575","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 THE AUTHORS. Published by Elsevier Limited on behalf of European Society for Medical Oncology; Originally published by BMJ.","name":"copyright","label":"Copyright"}],"article-number":"e000575"}}